Results 181 to 190 of about 54,702 (261)

Knowledge, Attitudes, and Prescribing Practices of Primary Healthcare Physicians Regarding Proton Pump Inhibitor Use in the United Arab Emirates: A Cross-Sectional Study. [PDF]

Cureus
Alameeri ZM, Alshemeili AR, Alhajri OA, Alketbi RM, Sajwani ZM.   +4 more
europepmc   +1 more source

Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors

British Journal of Clinical Pharmacology, EarlyView.
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem, Mohannad N. AbuHaweeleh, Humam Emad Rajha, Mhd Osama Rahhal, Ahmad Hamdan, Lina Naseralallah   +5 more
wiley   +1 more source

Proton Pump Inhibitor Use and Incident Hypertension in Menopausal Women. [PDF]

J Am Heart Assoc
Soliman AI, Wactawski-Wende J, Millen AE, Gray SL, Eaton CB, Hovey KM, Donneyong M, Saquib N, Mouton CP, Laddu D, Liu S, Shimbo D, Wassertheil-Smoller S, LaMonte MJ.   +13 more
europepmc   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

The Need for Objective Testing in Proton Pump Inhibitor-refractory Extraesophageal Gastroesophageal Reflux Disease. [PDF]

J Neurogastroenterol Motil
Kim SY.
europepmc   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

Primary carE PPi dEprescRibing (PEPPER) trial: a protocol for determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients. [PDF]

BMJ Open
Carbone F, Scheepers J, Van den Houte K, Laenen A, Tack J.   +4 more
europepmc   +1 more source

Artificial Cell Catalysts for Biotransformation: Design Principles and Process Integration

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Artificial cell catalysts are emerging as programmable biocatalytic platforms for sustainable molecular conversion. By reconstituting enzymes and functional modules within synthetic compartments, they combine the selectivity of biological catalysis with the design flexibility of synthetic materials.
Iori Kobayashi, Shogo Yoshimoto, Katsutoshi Hori   +2 more
wiley   +1 more source

The First Reported Case of Hybrid Argon Plasma Coagulation Ablation for Symptomatic Cervical Inlet Patches Refractory to Proton Pump Inhibitor Therapy. [PDF]

Turk J Gastroenterol
Chuah YY, Lee YY, Tseng PH, Hsieh SP, Chou CK, Shiue YL.   +5 more
europepmc   +1 more source

Transfersomes with core and surface‐loaded NF‐κB p65 siRNA for enhanced transdermal transfection and effective treatment of psoriasis

BMEMat, EarlyView.
TCPL, a transfersome with Tween 80 and PEI, enables efficient transdermal siNF‐κB delivery, resolving PEI's toxicity issue. It promotes lysosomal escape and effective transfection, silences NF‐κB, modulates immunity, and inhibits angiogenesis, alleviating psoriasis. With good biocompatibility, TCPL holds strong clinical translation potential. Schematic
Hui Xing, Yuhui Yang, Ziyi Zhao, Kai Lv, Yiran Shao, Zhi Zhang, Dong Ma   +6 more
wiley   +1 more source